Sandoz Sanguine On Market Opportunity Despite Biosimilar Neulasta Setback
Executive Summary
Questions from European regulators around Sandoz's market application for biosimilar pegfilgrastim have prompted the company to withdraw the drug's filing – a delay which could allow competitor biosimilar developers to launch ahead of the Novartis-owned company.